FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).

Computed tomography features of gastrointestinal linitis plastica: spectrum of findings in early and delayed phase imaging.

PURPOSE: To analyze the features of gastrointestinal linitis plastica obtained by computed tomography (CT). MATERIALS AND METHODS: We conducted a single-center, retrospective analysis of 45 cases of gastrointestinal tract linitis plastica collected over a 10-year period. "Linitis plastica" was defined based on histological characteristics. Primary and secondary linitis plastica were included. Two readers independently assessed the radiological findings (i.e., number of lesions, mass, wall thickening, and enhancement). RESULTS: The patient cohort comprised 23 men and 22 women with an average age of 63.2 years. The main presenting signs and symptoms were impaired general health and ascites (22/45 patients, 48.8%). The stomach was the affected organ in 68.3% of the cases, while the rectum was affected in 11.7% of the cases. Primary linitis was found in 73.3% of the cases, and solitary lesions were found in 77.8% of the cases. The most common CT finding was wall thickening (91.7%) with a complete disappearance of folds and enhancement of the entire wall at 2 min. Four lesions (6.6%) were described as masses, and only one (1.7%) was described as a wall atrophy. CONCLUSION: Linitis plastica can affect the entire digestive system. Its potentially secondary nature necessitates a systematic search for a primary tumor. An appropriate CT protocol is required to detect the specific radiological features of this fibrous cancer. CT can help confirm the diagnosis of linitis plastica, rule out differential diagnoses, and indicate the need for deep biopsies where possible.

[Hepatitis A acquired from an asymptomatic adopted child]. / Hépatite A transmise par un enfant adopté asymptomatique.

We report the case of acute hepatitis in a 36-year-old woman that was acquired from an adopted African child with asymptomatic active infection. At present, most experts do not screen for hepatitis A. However, adoptive parents should be vaccinated against hepatitis A because of the risk of unrecognized active infection in adopted children from countries in which infection is endemic.

[Pancreatic pseudocysts of the right hepatic lobe during acute biliary pancreatitis]. / Pseudokystes hépatiques du foie droit au décours d'une pancréatite aiguë biliaire.

The occurrence of pancreatic pseudocysts of the right hepatic lobe during acute biliary pancreatitis is a rare event. We report the unusual case of a 69-year-old woman who was hospitalised for biliary pancreatitis. The patient suffered from right hypochondrial pain. A CT-scan performed at day 12 showed pancreatic pseudocysts in the right hepatic lobe. A favorable outcome was obtained after percutaneous drainage. Most hepatic pseudocysts are described in the left hepatic lobe after alcoholic pancreatitis. Different hypotheses have been suggested to explain the extension of pancreatic pseudocysts in the liver, due to proteolytic effect of pancreatic enzymes that reach the lesser sac and then the liver either directly through the liver capsule, or indirectly through the hepatic hilum vessels, or the hepatic ligament. We suggest another reason for hepatic invasion: pancreatic enzymes could also cause liver damage, through the para - renal anterior space, often infiltrated during acute pancreatitis, reaching right hepatic lobe through area nuda.